{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:23:00Z","timestamp":1793658180858,"version":"4.5.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal number of induction chemotherapy (IC) cycles for locoregionally advanced nasopharyngeal carcinoma (LA-NPC) is debated. This study investigates if early cell-free Epstein-Barr virus (cfEBV) DNA clearance can personalise treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 1590 LA-NPC patients treated with IC+ chemoradiotherapy (2010\u20132023) with complete early cfEBV DNA data. COX regression identified independent prognostic factors, and receiver operating characteristic curves assessed predictive accuracy. Propensity score matching (PSM) balanced covariates between groups receiving different IC cycles. The primary outcome, progression-free survival (PFS) was analysed using Kaplan-Meier and log-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After the first IC cycle, 45.5% of patients had undetectable cfEBV DNA. Combining cfEBV DNA clearance, N-stage, and overall stage yielded the highest AUC for 5-year PFS (0.632). Patients were stratified into high- and low-risk groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Post-matching, low-risk patients receiving three IC cycles had better 5-year PFS than those receiving two (85.2% vs. 76.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.024), with no significant increase in grade 3\u20134 toxicities (30.36% vs. 24.29%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.157). High-risk patients showed no PFS benefit from additional cycles (63.2% vs. 61.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.960).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Early cfEBV DNA clearance predicts LA-NPC outcomes. Low-risk patients may benefit from an additional cycle of IC, while high-risk patients may require alternative strategies like immunotherapy or earlier chemoradiotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03401-5","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:14:45Z","timestamp":1774984485000},"page":"1557-1567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incorporating early cfEBV DNA clearance into clinical risk stratification to tailor induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma"],"prefix":"10.1038","volume":"134","author":[{"given":"Wan-Ping","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Jian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Na","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7133-3951","authenticated-orcid":false,"given":"Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"3401_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64\u201380.","journal-title":"Lancet"},{"key":"3401_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10555-024-10176-9","volume":"43","author":"ZY Su","year":"2024","unstructured":"Su ZY, Siak PY, Lwin YY, Cheah SC. Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. Cancer Metastasis Rev. 2024;43:919\u201339.","journal-title":"Cancer Metastasis Rev"},{"key":"3401_CR3","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.ijrobp.2008.07.062","volume":"73","author":"YP Mao","year":"2009","unstructured":"Mao YP, Xie FY, Liu LZ, Sun Y, Li L, Tang LL, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73:1326\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3401_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jnci\/dji084","volume":"97","author":"AT Chan","year":"2005","unstructured":"Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97:536\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"3401_CR5","doi-asserted-by":"publisher","first-page":"8461","DOI":"10.1200\/JCO.2004.00.3863","volume":"23","author":"L Zhang","year":"2005","unstructured":"Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol. 2005;23:8461\u20138.","journal-title":"J Clin Oncol"},{"key":"3401_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2003.06.158","volume":"21","author":"JC Lin","year":"2003","unstructured":"Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631\u20137.","journal-title":"J Clin Oncol"},{"key":"3401_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ijrobp.2010.03.024","volume":"80","author":"SZ Lai","year":"2011","unstructured":"Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80:661\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3401_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.radonc.2014.02.003","volume":"110","author":"AW Lee","year":"2014","unstructured":"Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, et al. Evolution of treatment for nasopharyngeal cancer-success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014;110:377\u201384.","journal-title":"Radiother Oncol"},{"key":"3401_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ijrobp.2019.06.2549","volume":"105","author":"XS Sun","year":"2019","unstructured":"Sun XS, Liu SL, Luo MJ, Li XY, Chen QY, Guo SS, et al. The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012. Int J Radiat Oncol Biol Phys. 2019;105:581\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3401_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509\u201320.","journal-title":"Lancet Oncol"},{"key":"3401_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381:1124\u201335.","journal-title":"N Engl J Med"},{"key":"3401_CR12","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.22.00327","volume":"40","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial. J Clin Oncol. 2022;40:2420\u20135.","journal-title":"J Clin Oncol"},{"key":"3401_CR13","unstructured":"National Comprehensive Cancer Network. Head and neck cancers. version 2.2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1437."},{"key":"3401_CR14","unstructured":"Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines Committee. CSCO clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (London, England). 2021;41:1023\u201352."},{"key":"3401_CR15","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamaoncol.2022.0122","volume":"8","author":"WZ Li","year":"2022","unstructured":"Li WZ, Lv X, Hu D, Lv SH, Liu GY, Liang H, et al. Effect of induction chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on failure-free survival for patients with stage iva to ivb nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 2022;8:706\u201314.","journal-title":"JAMA Oncol"},{"key":"3401_CR16","doi-asserted-by":"publisher","first-page":"e081557","DOI":"10.1136\/bmj-2024-081557","volume":"389","author":"WH Xie","year":"2025","unstructured":"Xie WH, Xiao WW, Chang H, Xu MJ, Hu YH, Zhou TC, et al. Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial. BMJ. 2025;389:e081557.","journal-title":"BMJ"},{"key":"3401_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S1470-2045(00)00019-X","volume":"1","author":"AJ Davis","year":"2000","unstructured":"Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol. 2000;1:86\u201393.","journal-title":"Lancet Oncol"},{"key":"3401_CR18","doi-asserted-by":"publisher","first-page":"14973","DOI":"10.18632\/oncotarget.7789","volume":"7","author":"YP Chen","year":"2016","unstructured":"Chen YP, Mao YP, Zhang WN, Chen L, Tang LL, Li WF, et al. Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensity matched analysis. Oncotarget. 2016;7:14973\u201382.","journal-title":"Oncotarget"},{"key":"3401_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2016.12.009","volume":"73","author":"H Liang","year":"2017","unstructured":"Liang H, Xiang YQ, Lv X, Xie CQ, Cao SM, Wang L, et al. Survival impact of waiting time for radical radiotherapy in nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area. Eur J Cancer. 2017;73:48\u201360.","journal-title":"Eur J Cancer"},{"key":"3401_CR20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/jmv.27440","volume":"94","author":"R Pramanik","year":"2022","unstructured":"Pramanik R, Arora S, Sharma P, Biswas A, Nayak B, Thakar A, et al. Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a nonendemic region. J Med Virol. 2022;94:720\u20138.","journal-title":"J Med Virol"},{"key":"3401_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of plasma Epstein-Barr Virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377:513\u201322.","journal-title":"N Engl J Med"},{"key":"3401_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75396-z","volume":"14","author":"Y Weng","year":"2024","unstructured":"Weng Y, Cai S, Li C, Xu Y, Pan Y, Huang Z, et al. Selection of induction chemotherapy cycles for stage N3 nasopharyngeal carcinoma based on pre-treatment plasma EBV DNA. Sci Rep. 2024;14:24484.","journal-title":"Sci Rep"},{"key":"3401_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106725","volume":"151","author":"C Ding","year":"2024","unstructured":"Ding C, Dai DY, Luo ZK, Wang GY, Dong Z, Qin GJ, et al. Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma. Oral Oncol. 2024;151:106725.","journal-title":"Oral Oncol"},{"key":"3401_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.oraloncology.2018.10.007","volume":"86","author":"L Peng","year":"2018","unstructured":"Peng L, Chen YP, Xu C, Tang LL, Chen L, Lin AH, et al. A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma. Oral Oncol. 2018;86:258\u201365.","journal-title":"Oral Oncol"},{"key":"3401_CR25","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/hed.26141","volume":"42","author":"Y He","year":"2020","unstructured":"He Y, Zhao Z, Wang Y, Chai J, He J, Wang J, et al. Optimizing number of cycles of induction chemotherapy for patients with nasopharyngeal carcinoma: retrospective survival analysis. Head Neck. 2020;42:2067\u201376.","journal-title":"Head Neck"},{"key":"3401_CR26","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ccell.2024.07.001","volume":"42","author":"J Lv","year":"2024","unstructured":"Lv J, Xu LX, Li ZX, Lin L, Wu CF, Quan TQ, et al. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: the EP-SEASON study. Cancer Cell. 2024;42:1401\u201314 e1404.","journal-title":"Cancer Cell"},{"key":"3401_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2021.05.022","volume":"153","author":"AWM Lee","year":"2021","unstructured":"Lee AWM, Lee VHF, Ng WT, Strojan P, Saba NF, Rinaldo A, et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer. 2021;153:109\u201322.","journal-title":"Eur J Cancer"},{"key":"3401_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02076-4","volume":"19","author":"CF Wu","year":"2021","unstructured":"Wu CF, Lin L, Mao YP, Deng B, Lv JW, Zheng WH, et al. Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA. BMC Med. 2021;19:193.","journal-title":"BMC Med"},{"key":"3401_CR29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/cac2.12100","volume":"40","author":"R Tan","year":"2020","unstructured":"Tan R, Phua SKA, Soong YL, Oon LLE, Chan KS, Lucky SS, et al. Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma. Cancer Commun. 2020;40:564\u201385.","journal-title":"Cancer Commun"},{"key":"3401_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ccell.2023.12.020","volume":"42","author":"XJ Du","year":"2024","unstructured":"Du XJ, Wang GY, Zhu XD, Han YQ, Lei F, Shen LF, et al. Refining the 8th edition TNM classification for EBV-related nasopharyngeal carcinoma. Cancer Cell. 2024;42:464\u201373 e463.","journal-title":"Cancer Cell"},{"key":"3401_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.5732\/cjc.012.10095","volume":"31","author":"WF Li","year":"2012","unstructured":"Li WF, Sun Y, Chen M, Tang LL, Liu LZ, Mao YP, et al. Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation. Chin J Cancer. 2012;31:579\u201387.","journal-title":"Chin J Cancer"},{"key":"3401_CR32","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/cncr.32770","volume":"126","author":"FP Chen","year":"2020","unstructured":"Chen FP, Huang XD, Lv JW, Wen DW, Zhou GQ, Lin L, et al. Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma. Cancer. 2020;126:2163\u201373.","journal-title":"Cancer"},{"key":"3401_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110032","volume":"190","author":"CL Huang","year":"2024","unstructured":"Huang CL, Wang GY, Lou JH, Chen L, Li QJ, Li KP, et al. Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up. Radiother Oncol. 2024;190:110032.","journal-title":"Radiother Oncol"},{"key":"3401_CR34","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cncr.20099","volume":"100","author":"JY Shao","year":"2004","unstructured":"Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A\/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004;100:1162\u201370.","journal-title":"Cancer"},{"key":"3401_CR35","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1200\/JCO.2012.46.0816","volume":"31","author":"LQ Tang","year":"2013","unstructured":"Tang LQ, Chen QY, Fan W, Liu H, Zhang L, Guo L, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography\/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2013;31:2861\u20139.","journal-title":"J Clin Oncol"},{"key":"3401_CR36","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1002\/cncr.25932","volume":"117","author":"X An","year":"2011","unstructured":"An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic\/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011;117:3750\u20137.","journal-title":"Cancer"},{"key":"3401_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11853-y","volume":"10","author":"J Lv","year":"2019","unstructured":"Lv J, Chen Y, Zhou G, Qi Z, Tan KRL, Wang H, et al. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun. 2019;10:3941.","journal-title":"Nat Commun"},{"key":"3401_CR38","doi-asserted-by":"publisher","first-page":"113336","DOI":"10.1016\/j.ejca.2023.113336","volume":"194","author":"SS Guo","year":"2023","unstructured":"Guo SS, Yang JH, Sun XS, Liu LZ, Yang ZC, Liu LT, et al. Reduced-dose radiotherapy for Epstein-Barr virus DNA-selected staged III nasopharyngeal carcinoma: a single-arm, phase 2 trial. Eur J Cancer. 2023;194:113336.","journal-title":"Eur J Cancer"},{"key":"3401_CR39","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1200\/JCO.21.01467","volume":"40","author":"XY Li","year":"2022","unstructured":"Li XY, Luo DH, Guo L, Mo HY, Sun R, Guo SS, et al. Deintensified chemoradiotherapy for pretreatment Epstein-Barr Virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized noninferiority trial. J Clin Oncol. 2022;40:1163\u201373.","journal-title":"J Clin Oncol"},{"key":"3401_CR40","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jama.2022.13997","volume":"328","author":"LL Tang","year":"2022","unstructured":"Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, et al. Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial. JAMA. 2022;328:728\u201336.","journal-title":"JAMA"},{"key":"3401_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.radonc.2021.12.029","volume":"167","author":"SQ Tang","year":"2022","unstructured":"Tang SQ, Chen L, Li WF, Chan ATC, Huang SH, Chua MLK, et al. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. Radiother Oncol. 2022;167:179\u201386.","journal-title":"Radiother Oncol"},{"key":"3401_CR42","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1200\/JCO.2006.07.7982","volume":"24","author":"SF Leung","year":"2006","unstructured":"Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24:5414\u20138.","journal-title":"J Clin Oncol"},{"key":"3401_CR43","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211052417","volume":"13","author":"FP Chen","year":"2021","unstructured":"Chen FP, Lin L, Liang JH, Tan SH, Ong EHW, Luo YS, et al. Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases. Ther Adv Med Oncol. 2021;13:17588359211052417.","journal-title":"Ther Adv Med Oncol"},{"key":"3401_CR44","doi-asserted-by":"crossref","unstructured":"Tang, LQ, Li, CF, Li, J, Chen, WH, Chen, QY, Yuan, LX, et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst. 2016;108.","DOI":"10.1093\/jnci\/djv291"},{"key":"3401_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106500","volume":"145","author":"G Wang","year":"2023","unstructured":"Wang G, Dong Z, Huang C, Du X, Chen L, Li K, et al. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2023;145:106500.","journal-title":"Oral Oncol"},{"key":"3401_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02463-5","volume":"20","author":"J Lv","year":"2022","unstructured":"Lv J, Wu C, Li J, Chen F, He S, He Q, et al. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics. BMC Med. 2022;20:268.","journal-title":"BMC Med"},{"key":"3401_CR47","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","volume":"39","author":"YP Chen","year":"2021","unstructured":"Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol. 2021;39:840\u201359.","journal-title":"J Clin Oncol"},{"key":"3401_CR48","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.xcrm.2024.101594","volume":"5","author":"W Jiang","year":"2024","unstructured":"Jiang W, Lv JW, Tang LL, Sun Y, Chen YP, Ma J. Enhancing efficacy and reducing toxicity: therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma. Cell Rep Med. 2024;5:101594.","journal-title":"Cell Rep Med"},{"key":"3401_CR49","doi-asserted-by":"publisher","first-page":"e1913619","DOI":"10.1001\/jamanetworkopen.2019.13619","volume":"2","author":"B Zhang","year":"2019","unstructured":"Zhang B, Li MM, Chen WH, Zhao JF, Chen WQ, Dong YH, et al. Association of chemoradiotherapy regimens and survival among patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1913619.","journal-title":"JAMA Netw Open"},{"key":"3401_CR50","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1093\/annonc\/mdt146","volume":"24","author":"PY OuYang","year":"2013","unstructured":"OuYang PY, Xie C, Mao YP, Zhang Y, Liang XX, Su Z, et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol. 2013;24:2136\u201346.","journal-title":"Ann Oncol"},{"key":"3401_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0360-3016(02)02724-4","volume":"53","author":"N Lee","year":"2002","unstructured":"Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3401_CR52","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7150\/jca.65315","volume":"13","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Chen K, Yang J, Liang Z, Qu S, Li L, et al. Optimize the number of cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis. J Cancer. 2022;13:426\u201335.","journal-title":"J Cancer"},{"key":"3401_CR53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2021.03.052","volume":"151","author":"FP Chen","year":"2021","unstructured":"Chen FP, Luo YS, Chen K, Li JY, Huo LQ, Shi L, et al. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma. Eur J Cancer. 2021;151:63\u201371.","journal-title":"Eur J Cancer"},{"key":"3401_CR54","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1002\/cam4.5256","volume":"12","author":"YT Jiang","year":"2023","unstructured":"Jiang YT, Chen KH, Liang ZG, Yang J, Qu S, Li L, et al. Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response. Cancer Med. 2023;12:4010\u201322.","journal-title":"Cancer Med"},{"key":"3401_CR55","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","volume":"75","author":"SM Cao","year":"2017","unstructured":"Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14\u201323.","journal-title":"Eur J Cancer"},{"key":"3401_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21795-z","volume":"12","author":"L Gong","year":"2021","unstructured":"Gong L, Kwong DL, Dai W, Wu P, Li S, Yan Q, et al. Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. Nat Commun. 2021;12:1540.","journal-title":"Nat Commun"},{"key":"3401_CR57","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jcsm.13196","volume":"14","author":"J Miao","year":"2023","unstructured":"Miao J, Wang L, Ong EHW, Hu C, Lin S, Chen X, et al. Effects of induction chemotherapy on nutrition status in locally advanced nasopharyngeal carcinoma: a multicentre prospective study. J Cachexia Sarcopenia Muscle. 2023;14:815\u201325.","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03401-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T19:01:59Z","timestamp":1779130919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03401-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,5]]}},"alternative-id":["3401"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03401-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center (B2025-634-01). As a retrospective analysis of anonymized clinical data, the need for individual patient consent was waived by the ethics committee. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}